BioSpace

Wegovy maker Novo shares slump as management grilled on pricing, M&A

Testosterone scripts for women rise, along with denials and delays

Novartis’ TREM2 drug fails Phase 2 ALS trial

Psychedelics Stock, Up 190% This Year, Flies High Again

Experts urge FDA to set clear safety and access standards for psychedelic drugs

No more Nordisk as Novo goes it alone amid rebranding push

Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

A ‘Transformative’ Narcolepsy Drug Opens New Opportunities in Neuroscience

Novartis Stock Tanks Following Third Major Pipeline Setback

Summit Packs A Punch For Merck's Keytruda

Newly approved pancreatic cancer drug shows promise in lung cancer

Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Alnylam’s heart drug troubles take center stage at a cardiology conference

Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial

The Race to Develop More Medicines Like the New Pancreatic Cancer Drug

Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal

RFK Jr. may upend how vaccine recommendations are categorized

Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings

Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.

For Narcoleptics, a 'New Chapter'

A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

The Surprising Reason This Biotech Plummeted 69%

EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.

FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety

Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low

Study reveals new role for tau, a top target for Alzheimer’s drug development

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

Utah reports 48 cyclospora cases, all but 5 could be tied to travel

Novo Nordisk shares slide after guidance disappoints investors

Why Pfizer Just Hiked Its Guidance By $500 Million

Micron, Bristol Myers, Palantir, Circle Internet, SpaceX, and More Stocks That Explain Today’s Market

Replimune’s twice-rejected melanoma drug prevails in FDA adcomm

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

The FDA has granted approval to Otsuka for Simtriyo, marking the introduction of the first triple reuptake inhibitor for the treatment of ADHD.

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

FDA staff flags data concerns about Capricor's therapy; shares plunge

Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Why Arrowhead Shot Sky-High, While Ionis Toppled

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

FDA releases 14 drug rejection letters after 3-month pause

FDA resumes releasing drug rejection letters after 3-month pause

This Week in Science: Knee Pain Relief, a Superconductor Record, And More!

A new minimally invasive procedure using tiny beads may significantly reduce knee osteoarthritis pain and delay the need for replacement surgery.

Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback

Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.

FDA’s top gene therapy regulator is leaving his role

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

The FDA has launched a new initiative to accelerate the review process for new pharmaceutical manufacturing facilities.

Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope

An experimental drug targeting pancreatic cancer is showing promising survival gains in clinical trials.

Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers